Oncological outcomes according to the treatment modality based on the size of rectal neuroendocrine tumors: a single-center retrospective study

Son, Jimin; Park, In Ja; Yang, Dan; Kim, Jisup; Kim, Kyoung-Jo; Byeon, Jeong‐Sik; Hong, Seung Mo; Kim, Young Il; Kim, Jong Beom; Lim, Seok‐Byung; Yu, Chang Sik; Kim, Jin Cheon

doi:10.1007/s00464-021-08527-6

Cited by 10 publications

(6 citation statements)

References 35 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Most rectal NETs as stated earlier are < 10 mm and the majority are grade 1 tumours. A large series from Korea of 567 patients undergoing endoscopic resection demonstrated 79.9% as grade 1 tumours and the remaining lesions were grade 2 [15], and similar findings from other studies in Japan demonstrate that over 90% of rectal NETS were grade 1 and 62% in a study by Yu et al from China [16].…”

Section: This Article Is Part Of the Topical Collection On Neuroendocrine Neoplasmssupporting

confidence: 70%

“…This is primarily directed by the expertise available at different institutions. The largest published series from Southeast Asia have examined different endoscopic resection techniques using endoscopic mucosal resection (EMR), cap assisted EMR, band assisted EMR, or endoscopic mucosal dissection (ESD) [9,10,15,23]. The consensus is that the standard snare polypectomy is insufficient to enable clear resection margins in the majority of cases.…”

Section: This Article Is Part Of the Topical Collection On Neuroendocrine Neoplasmsmentioning

confidence: 99%

See 1 more Smart Citation

Rectal Neuroendocrine Neoplasms: Why Is There a Global Variation?

Cope

Srirajaskanthan

2022

Curr Oncol Rep

View full text Add to dashboard Cite

Purpose of Review This review examines the variation in incidence of rectal neuroendocrine tumours across the globe. Rectal neuroendocrine tumours are a common type of gastrointestinal NET with an increasing incidence reported over the last 30 years. Recent Findings There have been a number of publications examining the epidemiology of neuroendocrine tumours across the world. These have utilized a variety of different methodologies to examine both incidence of prevalence of NETs. We review the data published and describe any causative factors and findings regarding the epidemiology of rectal NETs. Summary Rectal NETs account for 1–2% of all rectal cancers and are commonly diagnosed between 50–60 years of age. Most lesions are identified by chance at colonoscopy, commonly during colon cancer screening procedures, which is reflected in part in the age at diagnosis. Most lesions are small in size, < 10 mm and can be managed with endoscopic resection rather than requiring surgery. The highest incidence is reported in people of Asian ethnicity, with a tenfold increased incidence reported in some series compared with white population. There is also an increased incidence in Black and Hispanic population as identified through the Surveillance, Epidemiology and End Results (SEER) database. Endoscopic assessment of lesions is variable globally. Future work to better understand the cause of ethnic variation and development of comprehensive cancer registries would be helpful.

show abstract

Section: This Article Is Part Of the Topical Collection On Neuroendocrine Neoplasmssupporting

confidence: 70%

Section: This Article Is Part Of the Topical Collection On Neuroendocrine Neoplasmsmentioning

confidence: 99%

Rectal Neuroendocrine Neoplasms: Why Is There a Global Variation?

Cope

Srirajaskanthan

2022

Curr Oncol Rep

View full text Add to dashboard Cite

show abstract

“…For example, of 644 NETs removed during the past 16 years, 91% being ≤10 mm in diameter, 88% underwent endoscopic removal and 7% underwent LE. 23 The risk of metastasis increases with increasing tumour size, being <3%, 4%-20%, and 30%-80% in patients with tumours <10, 10-20, and >20 mm, respectively. 24 The one patient in this study with anorectal GIST was treated with imatinib for 6 months; after no further improvement was observed, this patient underwent APR and has survived to date without recurrence for 100 months.…”

Section: Discussionmentioning

confidence: 95%

“…Although ARNETs can be removed by radical resection, we have generally utilised EMR or ESD to remove tumours of long diameter ≤10 mm. For example, of 644 NETs removed during the past 16 years, 91% being ≤10 mm in diameter, 88% underwent endoscopic removal and 7% underwent LE 23 . The risk of metastasis increases with increasing tumour size, being <3%, 4%–20%, and 30%–80% in patients with tumours <10, 10–20, and >20 mm, respectively 24 .…”

Section: Discussionmentioning

confidence: 99%

Implementation of robot‐assisted curative resection for rare anorectal tumours on the basis of individualised treatment

Kim

Jung

et al. 2021

Robotics Computer Surgery

Self Cite

View full text Add to dashboard Cite

Purpose: To evaluate the validity of robot-assisted curative operation for rare anorectal tumours, characterised by biological heterogeneity and anatomical complexity. Methods:The present study evaluated 16 consecutive patients including three with anorectal squamous cell carcinoma (ARSCC), four with anorectal mucosal melanoma (ARMM), seven with anorectal neuroendocrine tumour (ARNET), and two with other types of anorectal tumours. Results:Of the three patients with ARSCC after chemoradiotherapy, two underwent abdominoperineal resection (APR), and one underwent ultralow anterior resection (uLAR)/total intersphincteric resection (ISR), surviving 56-76 months without recurrence. Of the four ARMM patients, APR and uLAR/total ISR were conducted in two patients, respectively, with variable survival outcomes. All seven patients with ARNET were treated with uLAR/ISR and LAR, surviving for 5-106 months to date. Conclusions:Because most anorectal tumours are confined to the dermal and submucosal layers, robotic anorectal function preserving ISR is expected to achieve R0 resection.

show abstract

“…Previous studies reported a correlation between primary tumor size and the likelihood of lymph node metastases in r-NETs [3,10,11,[20][21][22][23][24][25][26][27][28]. Therefore, the National Comprehensive Cancer Network (NCCN) guidelines and the latest ENETS guidelines recognize the identification of tumor size as a major parameter to determine the patient prognosis and therapy options [5,29].…”

Section: Discussionmentioning

confidence: 99%

Assessment of the Risk of Nodal Involvement in Rectal Neuroendocrine Neoplasms: The NOVARA Score, a Multicentre Retrospective Study

Ricci

Pusceddu

Panzuto

et al. 2022

JCM

View full text Add to dashboard Cite

Rectal neuroendocrine tumors (r-NETs) are rare tumors with overall good prognosis after complete resection. However, there is no consensus on the extension of lymphadenectomy or regarding contraindications to extensive resection. In this study, we aim to identify predictive factors that correlate with nodal metastasis in patients affected by G1–G2 r-NETs. A retrospective analysis of G1–G2 r-NETs patients from eight tertiary Italian centers was performed. From January 1990 to January 2020, 210 patients were considered and 199 were included in the analysis. The data for nodal status were available for 159 cases. The nodal involvement rate was 9%. A receiver operating characteristic (ROC) curve analysis was performed to identify the diameter (>11.5 mm) and Ki-67 (3.5%), respectively, as cutoff values to predict nodal involvement. In a multivariate analysis, diameter > 11.5 mm and vascular infiltration were independently correlated with nodal involvement. A risk scoring system was constructed using these two predictive factors. Tumor size and vascular invasion are predictors of nodal involvement. In addition, tumor size > 11.5 mm is used as a driving parameter of better-tailored treatment during pre-operative assessment. Data from prospective studies are needed to validate these results and to guide decision-making in r-NETs patients in clinical practice.

show abstract

Oncological outcomes according to the treatment modality based on the size of rectal neuroendocrine tumors: a single-center retrospective study

Cited by 10 publications

References 35 publications

Rectal Neuroendocrine Neoplasms: Why Is There a Global Variation?

Rectal Neuroendocrine Neoplasms: Why Is There a Global Variation?

Implementation of robot‐assisted curative resection for rare anorectal tumours on the basis of individualised treatment

Assessment of the Risk of Nodal Involvement in Rectal Neuroendocrine Neoplasms: The NOVARA Score, a Multicentre Retrospective Study

Contact Info

Product

Resources

About